HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.

Huang X, Wang S, Lee CK, Yang X, Liu B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett. 2011 Aug 01; 307(1):72-79.

View in: PubMed

subject areas

Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Apoptosis
Benzamides
Blotting, Western
Breast Neoplasms
Cell Proliferation
Drug Resistance, Neoplasm
Drug Synergism
Female
Histone Deacetylase Inhibitors
Humans
Immunoprecipitation
Proto-Oncogene Proteins c-akt
Pyridines
Receptor, erbB-2
Receptor, erbB-3
Tumor Cells, Cultured

authors with profiles

Xiaohe Yang

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support